(R)-tert-butyl (1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate | 1352719-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (R)-tert-butyl (1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate
• 英文别名: (2R)-N-(2-t-butoxycarbonylamino)propylphthalimide；tert-butyl N-[(2R)-1-(1,3-dioxoisoindol-2-yl)propan-2-yl]carbamate
• CAS: 1352719-38-0
• 化学式: C₁₆H₂₀N₂O₄
• 分子量: 304.346
• InChiKey: NMERJCWBQHVGAD-SNVBAGLBSA-N

物化性质

• 沸点：
  447.2±28.0 °C(Predicted)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  75.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl (1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate 在 盐酸 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 22.0h， 生成 N-[(2R)-1-(1,3-dioxoisoindol-2-yl)propan-2-yl]-3-(2-fluorophenyl)propanamide
  参考文献：
  名称：

  [EN] PANTOTHENAMIDE ANALOGUES
  [FR] ANALOGUES DE PANTOTHÉNAMIDE

  摘要：

  公开号：

  WO2016072854A3
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 偶氮二甲酸二异丙酯 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 (R)-tert-butyl (1-(1,3-dioxoisoindolin-2-yl)propan-2-yl)carbamate
  参考文献：
  名称：

  PAK4抑制剂4-(3-1H-吲唑基)氨基喹唑啉衍生物的设计、合成及抗癌活性评价

  摘要：

  基于支架跳跃策略，开发了一系列新型 4-(3-1 H-吲唑基)氨基喹唑啉衍生物作为 PAK4 抑制剂。发现化合物27e、27g、27i和27j表现出针对PAK4的有效抑制活性(IC 50 分别＝10、13、11和9nM)。随后的细胞实验表明，化合物27e对A549细胞具有最强的抗增殖活性，IC 50值为0.61 μM，略好于PF-3758309。进一步的抗癌机制研究表明，化合物27e以浓度依赖性方式显着诱导A549细胞凋亡，并阻断细胞周期G0/G1期。提出了化合物27e和PAK4之间的对接模型来阐明其可能的结合模式。作为一种有前景的PAK4抑制剂，化合物27e可作为开发新型PAK4靶向抗癌药物的候选药物。

  DOI：

  10.1016/j.bmc.2023.117501

文献信息

• Synthesis of imidacloprid derivatives with a chiral alkylated imidazolidine ring and evaluation of their insecticidal activity and affinity to the nicotinic acetylcholine receptor
  作者：Hisashi Nishiwaki、Mituhiro Kuriyama、Hikaru Nagaoka、Akira Kato、Miki Akamatsu、Satoshi Yamauchi、Yoshihiro Shuto

  DOI：10.1016/j.bmc.2012.09.007

  日期：2012.11

  imidazolidine ring were asymmetrically synthesized to evaluate their insecticidal activity against adult female housefly, Musca domestica, and affinity to the nicotinic acetylcholine receptor of the flies. The bulkier the alkyl group, the lower was the receptor affinity, but the derivatives methylated and ethylated at the R-5-position of the imidazolidine ring were equipotent to the unsubstituted compound. Quantitative

  不对称合成了一系列具有烷基化咪唑烷环的吡虫啉（IMI）衍生物，以评估其对成年雌性家蝇Musca domestica的杀虫活性以及对果蝇的烟碱乙酰胆碱受体的亲和力。烷基越大，受体亲和力越低，但是在咪唑烷环的R -5-位甲基化和乙基化的衍生物与未取代的化合物等价。受体亲和力的定量结构-活性关系（QSAR）分析表明，将取代基引入咪唑烷环基本上是不利的，但在R处引入取代基如果尺寸较小，则允许-5-位置。合成衍生物与受体的结合模型支持QSAR分析，表明在配体结合位点R -5-位置周围的短烷基存在空间。此外，在杀虫活性和受体亲和力之间观察到正相关，这表明即使修饰了咪唑烷环，受体亲和力也是影响杀虫活性的主要因素。
• Affinity to the Nicotinic Acetylcholine Receptor and Insecticidal Activity of Chiral Imidacloprid Derivatives with a Methylated Imidazolidine Ring
  作者：Hisashi NISHIWAKI、Hikaru NAGAOKA、Mituhiro KURIYAMA、Satoshi YAMAUCHI、Yoshihiro SHUTO

  DOI：10.1271/bbb.100846

  日期：2011.4.23

  asymmetrically methylated imidazolidine ring were synthesized. Their affinity to the nicotinic acetylcholine receptor of housefly Musca domestica and insecticidal activity against the housefly were measured. The compound with a 5R-methylated imidazolidine ring demonstrated intrinsic activity comparable to that of the unsubstituted compound. Most of the compounds were synergized by oxygenase inhibitors

  合成了具有不对称甲基化咪唑烷环的四种吡虫啉衍生物。测量它们对家蝇家蝇的烟碱乙酰胆碱受体的亲和力和对家蝇的杀虫活性。具有5R-甲基化的咪唑烷环的化合物显示出与未取代的化合物相当的固有活性。大多数化合物是由加氧酶抑制剂协同作用的。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
  申请人：FUJIFILM Corporation

  公开号：EP2589592A1

  公开（公告）日：2013-05-08

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl g roup, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R4 and R5 e ach independently represent a hydrogen atom; and R2 and R4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种化合物和药物组合物，其具有优异的抑制 Syk 的活性。本发明提供了一种烟酰胺衍生物，由以下式（I）表示 其中 R1 代表卤素原子；R2 代表 C1-12 烷基、C2-12 烯基、C2-12 炔基、C3-8 环烷基、芳基、ar-C1-6 烷基或杂环基，每个基团可选择具有至少一个取代基；R3 代表芳基或杂环基，每个基团可选择具有至少一个取代基；以及 R4 和 R5 分别独立地代表一个氢原子；R2 和 R4 可与它们结合的氮原子一起形成一个环状氨基，该氨基可选择具有至少一个取代基）或其盐，以及一种用于治疗 Syk 相关疾病的药物组合物，该药物组合物包含烟酰胺衍生物或其盐。
• Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines
  作者：Thomas Hunt、Hazel C. Atherton-Watson、Stephen P. Collingwood、Kevin J. Coote、Sarah Czarnecki、Henry Danahay、Catherine Howsham、Peter Hunt、Derek Paisley、Alice Young

  DOI：10.1016/j.bmcl.2012.02.067

  日期：2012.4

  We report the synthesis and biological evaluation of a series of novel alpha-branched pyrazinoyl quaternary amines for their ability to block ion transport via the epithelial sodium channel (ENaC) in human bronchial epithelial cells (HBECs). Compound 12g has an IC50 of 30 nM and is highly efficacious in the Guinea-pig tracheal potential difference (TPD) model of ENaC blockade with an ED50 of 1 mu g kg(-1) at 1 h. In addition the SAR results demonstrate for the first time the chiral nature of the binding site of human ENaC. As such, pyrazinoyl quaternary amines represent a promising new class of ENaC blockers for the treatment of cystic fibrosis that are structurally distinct from the pyrazinoyl guanidine chemotype found in prototypical ENaC blockers such as amiloride. (C) 2012 Elsevier Ltd. All rights reserved.